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Background: Carrier screening for cystic ﬁbrosis is not widely available in Australia, partly due to concerns regarding its cost-effectiveness. The
beneﬁt of information from pregnancy to pregnancy has not been widely considered in existing cost-effectiveness analyses.
Methods: A decision tree was constructed estimating costs and outcomes from screening, including both initial and subsequent pregnancies.
Effectiveness was expressed in terms of CF births averted. Costs were collected using a health service perspective. All costs and outcomes were
discounted at 5% per annum.
Results: Screening reduced the annual incidence of CF births from 34 to 14/100,000 births (an aggregate number of CF births of 100.9 and 41.9
respectively). In initial pregnancies, costs in the screening arm (A$16.6 million/100,000 births) exceed those in the non-screening arm (A
$13.4 million/100,000 births). The incremental cost per CF birth in initial pregnancies is therefore approximately A$150,000. However, this was re-
versed for subsequent pregnancies, in that the pre-collected information reduces the incidence of CF in subsequent pregnancies at low additional costs.
When aggregated, the results suggest screening is likely to be cost-saving.
Conclusions: The introduction of national carrier screening for cystic ﬁbrosis should be considered, as it is likely to reduce CF incidence at an
acceptable (potentially negative) cost.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Australia; Screening; Cost-effectiveness; Economic evaluation1. Introduction
Carrier screening for cystic fibrosis (CF) has been possible since
the discovery of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene. [1,2] Despite this technological advance,
there have been few population-based carrier screening programs
introduced. An early pilot program in Edinburgh used a couple
screening model and halved the live birth incidence of CF [3].☆ Declarations: Martin Delatycki is a consultant to Healthscope Pathology.
⁎ Corresponding author at: Centre for Health Economics Research and Evaluation
(CHERE) University of Technology, Sydney POBOX 123, Broadway, New South
Wales 2007, Australia. Tel.: +61 295144732; fax: +61 295144730.
E-mail addresses: Richard.norman@chere.uts.edu.au (R. Norman),
kees.vangool@chere.uts.edu.au (K. van Gool), jane.hall@chere.uts.edu.au
(J. Hall), martin.delatycki@ghsv.org.au (M. Delatycki),
John.Massie@rch.org.au (J. Massie).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.02.007Fee for service pre-conception and prenatal screening are widely
practiced in the United States, but do not receive government sub-
sidy. Recent guidance from the American College of Obstetricians
and Gynecologists suggested that CF screening continues to be
offered to women of reproductive age [4]. A small fee for service
program has been operating in Victoria, Australia since 2006 but
does not attract government financial support [5].
A key factor for policy makers in funding decisions is an
understanding of the economic implications of screening. In
a resource-constrained environment, social decision-making
has become increasingly reliant on the evaluation of costs and
outcomes in parallel, as typified by the Pharmaceutical Benefits
Advisory Committee's (PBAC) central role in determining public
subsidy of new pharmaceuticals in Australia.
There are several cost-effectiveness analyses of CF carrier
screening, that have been summarised in a systematic reviewby Elsevier B.V. All rights reserved.
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range of settings and screening strategies (e.g. stepwise, prena-
tal, pre-conceptional). The review also demonstrated heteroge-
neity in study design, model inputs and outcome measurement,
making generalisability of results difficult. Based on the find-
ings of this review, it is apparent that there is wide divergence
in results. For example, the cost per CF baby averted through
prenatal screening in a primary care setting ranges from nega-
tive (i.e. it is cost-saving) [7] through to US$386,773 [8]. At
the time of the review, no study explored the costs and benefits
of CF screening in Australia. However, a subsequent cost-
effectiveness analysis did investigate prenatal screening in
Australia [9]. This concluded that prenatal screening using a
range of different timing strategies was unlikely to be cost-
saving.
One important consideration in this study which was not
addressed in the studies reported in the systematic review [6]
(and also the more recent Australian study) [9] is to evaluate
the impact of screening on subsequent reproduction decisions.
This is important as providing parents with information in ini-
tial pregnancies impacts on their decisions in any subsequent
pregnancies. For example, if a couple knows they are both car-
riers, they may decide to pursue in vitro fertilisation (IVF), or
use prenatal diagnosis or to abstain from reproduction. It would
be expected that parents taking up these options would lead to a
reduction in the number of CF infants, and also the costs of treat-
ing CF and associated conditions (although IVF and prenatal di-
agnosis involve other costs). Similarly, identifying parents as
non-carriers has implications for subsequent pregnancies, not in
terms of reducing CF incidence, but in eliminating the need for
subsequent testing.
The aim of this study is to provide information to decision
makers regarding the optimal approach to CF screening within a
resource-constrained environment. In particular, we aim to explore
the impact of information retention on the cost-effectiveness of
carrier screening. The screening options considered in this
study are (i) no screening, (ii) optional pre-conceptional
screening followed by optional prenatal screening for those
who do not take up pre-conceptional screening. We present a
decision tree contrasting costs and outcomes associated with
carrier screening approaches for CF based on the experience
in Victoria that could be used across Australia.2. Methods
The economic evaluation consisted of two components. The
first component considered the costs and outcomes accruing to
infants whose parents had no information regarding their carrier
status from previous pregnancies (i.e. a screening naïve popula-
tion). This population was termed initial pregnancies in this
study. The second component of the economic evaluation
considered the costs and outcomes accruing to any subsequent
infants. For these infants, parents have prior knowledge regarding
their carrier status, and this was reflected in the pathways fol-
lowed by these infants. This population was termed subsequent
pregnancies.2.1. Initial pregnancies
A decision tree was built based on the Victorian pilot program
[5]. A decision tree is a technique commonly used in cost-
effectiveness analysis to describe the pathways an individual
can follow with respect to a condition, and then to ascribe proba-
bilities, costs and outcomes to each of the possible pathways (also
called branches). Using these estimates of probabilities, costs and
outcomes, two or more competing strategies (such as screening
and not screening) can be compared. In this decision tree, both
pre-conceptional and prenatal screenings were offered. The key
elements of the tree are reproduced in Fig. 1. The decision tree
was built in TreeAge Pro 2011, a software designed specifically
for this type of conceptual problem.
Fig. 1 is simplified, as it does not show the pathways occurring
following a false negative result (or a false positive, but the model
assumes 100% specificity). While these are included in the model
(available on request), existing studies generally assumed high
sensitivity, meaning that very few couples would populate those
branches of the decision tree.
Screening prenatally and pre-conceptionally has a number of
similar features. The key difference between the arms is that the
latter allows for IVF or abstention from reproduction in the first
instance for couples identified as being carriers. For prenatal
screening, these options only exist for subsequent pregnancies.
To complete this analysis, we had to make a number of sim-
plifying assumptions. We assumed parenting partnerships are
stable; carrier status information is remembered for subsequent
pregnancies; and following a negative test result, couples pro-
ceed with pregnancy rather than pursuing further testing (e.g.
chorionic villus sampling (CVS)).2.2. Model inputs
The parameters required to populate the model are presented
in Table 2. All costs are in Australian 2010 dollars unless
stated.2.3. Screening costs
The international evidence on the cost of screening is vari-
able, providing a broad range of values [6]. This is partly due
to different cost bases in different countries and settings, but
also reflects the different cost components included in the esti-
mates. Existing Australian evidence regarding the marginal cost
of screening suggests a figure of $116.77 per test for pre-natal
screening [9]. This consisted of blood collection ($10), DNA
extraction ($11.27), screening test consumables ($31.95) and
screening test labour ($63.77). These figures are based on a
10-mutation panel as recommended by the Human Genetics
Society of Australasia CF carrier screening position statement
(available at www.hgsa.org.au). These figures are likely to rep-
resent an overestimate for a national screening program as they
are both likely to include aspects of fixed costs which could be
shared, and would be subject to economies of scale under a
larger program. Thus, the analysis biases in favour of not
Fig. 1. Decision tree.
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average cost.2.4. Other medical costs
The cost of termination was estimated using Australian
Diagnosis-Related Group data from 2008 to 2009. These data
provide an estimate of the total cost of managing a specific
type of patient including a wide range of different types of
cost. In this case, we used DRG O05Z, which estimates the
total cost of a termination to be $1708. CVS costs are estimated
using Medical Benefits Schedule Item number 16603 ($115.20).
The costs of an IVF cycle were estimated to be between $6000
and $9000; for the model we assumed a midpoint of $7500
[10]. We do not know the number of IVF cycles per couple con-
tingent on choosing IVF as a result of CF screening results. It is
likely to be below the general IVF population as these couples
are less likely to have fertility barriers; in our analysis, we have
conservatively assumed one cycle per couple and tested the
sensitivity of the result to this.
Lifetime CF management costs were estimated by Van Gool
et al. [11]. In this, the lifetime costs of management of a CF pa-
tient were estimated using Australian registry data of CF patients
in 2003–2005. The lifetime cost of managing a CF patient was
estimated to be $336,000, assuming a 5% discount rate. This
includes costs incurred in the inpatient setting (58%) and phar-
maceuticals (29%), with the remainder consisting of medical
services (including transplants), diagnostic testing and compli-
cations management.Table 1
Model memory.
Male carrier Male not carrier
True
positive
False
negative
True
negative
False
positive
Female carrier True positive B C A B
False negative C a C a A a A a
Female not carrier True negative A a A a A a A a
False positive B A A B
A: All subsequent babies do not have CF so no further costs are incurred.
B: All subsequent babies are dependent on choice between IVF, becoming
pregnant and using prenatal screening or abstaining from reproduction.
C: All subsequent babies are not subject to screening, and have a 25% chance of
having CF (i.e. probability of baby with two carrier parents having CF).
a Males are not screened following a negative female result.2.5. Outcomes
A screening program has a variety of relevant outcomes,
including carrier status detection, reassurance to non-carrier
parents, identification of fetuses with CF, reassurance of parents
with a non-CF baby, information to all prospective parents, or
something more general such as (quality-adjusted) years of life.
For this study, the cost per CF birth averted was specified as
the primary outcome of interest. Using CF births as an outcome
measure is limited as it is not comparable to outcomes in other
areas of medicine (and health more generally). This means it is
difficult to interpret for a policymaker facing a wide range of pos-
sible uses of scarce resources. While quality-adjusted life years
(QALYs) represent the gold-standard outcome measure for
economic evaluation, they include some ethically questionable
assumptions in situations in which termination can occur [6].
For example, can we reasonably assume that a CF-baby averted
will be followed by a healthy infant (either through CVS testing
of subsequent pregnancies or IVF)? This is clearly contentious
and we therefore do not follow this approach.
2.6. Perspective and discount rate
Costs were collected from a healthcare system perspective.
Thus, issues such as productivity were excluded. With the ex-
ception of the costs of treating people with CF, all costs are
immediate so are not discounted. The lifetime costs of manag-
ing patients with CF were generated using a 5% discount rate;
the reason for doing this is that it is the standard discount rate
recommended in Australian economic evaluations of health
technologies [12].
2.7. Sensitivity analysis
A univariate sensitivity analysis was conducted, varying each
model parameter within a range representing plausible high
and low values (reported in Table 2). The systematic review
of Radhakrishnan et al. provides ranges for many of the param-
eters [6]. The discount rate applied to the future healthcare
costs of treating an individual with CF is not considered in
the sensitivity analysis. This is because the range of discount
rates (i.e. 0–10%) considered by Van Gool et al. produce lifetime
costs of care similar to those outlined in Table 2 (i.e. increasing or
decreasing the cost by 50%). The results are presented in a Tornado
plot identifying the parameters to which the conclusion is most
sensitive. The analysis was repeated including and excluding
Table 2
Model parameters and assumptions for sensitivity analysis.
Parameter Value Source Range (for use in sensitivity analysis)
Carrier rate 0.04 Massie et al. 2000 ±50%
Cost of CVS $115.20 MBS item number ±50%
Cost of lifetime CF treatment $336,000 Van Gool et al. 2010 ±50%
Cost of testing $116.77 Maxwell et al. 2010 ±50%
Cost of termination $1708 AR-DRG ±50%
Cost of IVF $7500 Chambers et al. 2008 ±50%
Probability mortality (CVS) 0.013 Lieu 1994 0.0075–0.013 (Radhakrishnan et al. 2008)
Probability CVS test if 2+ve 0.9 Radhakrishnan et al. 2008 a 0.75–1 (Radhakrishnan et al. 2008)
Probability male tests if female+ve 0.94 Nielsen 2002 0.84–1.00 (assumption)
Probability female tests (prenatal) 0.80 Nielsen 2002 0.5–1 (Radhakrishnan et al. 2008)
Probability female tests (preconceptional) 0.20 Assumption 0.1–1 (Radhakrishnan et al. 2008)
Probability termination if CVS+ve 0.90 Radhakrishnan et al. 2008 b 0.3–1 (Radhakrishnan et al. 2008)
Sensitivity CVS 1 Radhakrishnan et al. 2008 Not considered as all existing studies assume 1
Specificity CVS 1
Test sensitivity 0.9 Radhakrishnan et al. 2008 c 0.85–1 (Radhakrishnan et al. 2008)
Test specificity 1 Radhakrishnan et al. 2008 0.99–1 (Radhakrishnan et al. 2008)
Prob (IVF) if both+ve 0.2 Assumption 0–1 (see note d below)
Prob (abstain) if both+ve 0.2 Assumption
Prob (postnatal diagnosis) if both+ve 0.6 Assumption
a Radhakrishnan et al. identified that assumptions of foetal diagnosis following confirmation of carrier status ranged from 75% to 100%. A figure of 90%was selected to
represent a typical value.
b Radhakrishnan et al. identified that assumptions of termination following identification of a CF fetus ranged from 80% to 95%. A figure of 90% was selected to
represent a typical value.
c Radhakrishnan et al. identified that assumptions of test sensitivity in a general population ranged from 85% to 100%. A figure of 90% was selected to represent a
typical value.
d As these probabilities are mutually exhaustive, increasing one probability has to be reflected in a reduction in one or both of the other two. For the sensitivity
analysis, this study explores the effect of extreme distributions between the three, assuming in turn that all parents enter IVF, that all parents abstain, and that all
parents use prenatal diagnosis.
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choices in subsequent infants.
2.8. Subsequent pregnancies
To model subsequent pregnancies, we categorised these into
three groups defined by common patterns of screening and risk
within each group. We constructed three supplementary deci-
sion trees A, B and C identifying the likelihood of a CF baby
(as well as any other options available to these parents, such
as abstention from reproduction) in subsequent pregnancies
based on screening results from a previous pregnancy. These
sub-trees consist solely of the probability of a CF infant
(which is described below), and the costs associated with
each group. If parents cannot have a CF infant in subsequent
pregnancies (because at least one of the parents is a non-
carrier), they enter sub-tree A. If both parents received a posi-
tive test result (in the sense that they are identified as carriers)
for the initial pregnancy (and hence are carriers as we assumed
specificity to be 1), they enter sub-tree B. In sub-tree B, a cou-
ple chooses between no further reproduction, becoming preg-
nant and use prenatal diagnosis, or IVF (with pre-implantation
genetic diagnosis, (PGD)). It was therefore assumed that no
parents both identified as carriers would pursue a pregnancy
without at least prenatal testing of the infant. Also, if parents
have a CF child irrespective of the screening results from an ini-
tial pregnancy, they enter model B. If the female receives afalse negative (and hence her partner is not invited for screen-
ing), the couple may enter sub-tree C in which no screening
is undertaken in subsequent pregnancies but there remains a
chance of a CF baby. This occurs if the father is a carrier (a
4% chance in the base case). If the parents are not screened,
all parents who are both carriers, but did not have a CF baby
in the initial pregnancy, enter sub-tree C. This allocation of par-
ents to these options is presented in Table 1.
Infants in each of the three supplementary decision trees
have different probabilities of CF than those screened in the ini-
tial program (termed initial infants). This is because their par-
ents' carrier status has been identified (or not in the case of
sub-tree C). To identify the importance of these changing prob-
abilities, it is first necessary to identify the relative numbers of
initial and subsequent infants. Australian Bureau of Statistics
data (2068.0–2006 Census tables) were used to identify the
mean number of infants per mother contingent on having at
least one child. Data from the 44–49 year old cohort was
used as they are the youngest cohort likely to have no addition-
al children. For this cohort, the average mother had 1.484 sub-
sequent children after their first born. The total number of
subsequent children per year is then divided between the termi-
nal (right-hand side) nodes in the decision tree, assigned to one
of the sub-trees A–C, and the number of CF infants and costs
associated with subsequent pregnancies were estimated. Note
that we have assumed that parents with positive CF status will
decide to have a similar number of children compared to the
285R. Norman et al. / Journal of Cystic Fibrosis 11 (2012) 281–287general population. This assumption is to some extent verified
by results from the Australian Cystic Fibrosis Data Registry
(ACFDR) that show that 20% of CF patients have siblings
with CF (available at http://www.cysticfibrosis.org.au/pdf/
Cystic_Fibrosis_in_Australia_2009.pdf). Given that parents
with positive carrier status have a 1 in 4 chance of having a
baby with CF, this would suggest that most CF patients have a
sibling. The results including subsequent pregnancies are consid-
ered in univariate sensitivity analysis using the same approach
as that undertaken for initial pregnancies.
3. Results
In the initial child cohort, prenatal screening was estimated
to reduce the number of CF births by approximately 53%. For
subsequent children, 117.0/100,000 couples ended in group
B, in which any future reproduction was assumed to take
place using IVF or PND. This compared with 40.0/100,000 in
the no screening group, reflecting the CF births (0.25∗carrier
rate^2). Screening reduced the population in group C from
120.0/100,000 to 43.3/100,000. In this group, subsequent preg-
nancies have a 25% chance of being CF as both parents are
carriers.
If no screening occurs, the number of CF infants in Australia
is estimated to be 40.0/100,000 in initial pregnancies, and 30.0/
100,000 in subsequent pregnancies (as one quarter of carrier
couples will have their carrier status revealed by having a CF
baby). Given the relative size of the two groups, this equates
to 34.0/100,000 in all pregnancies, or 100.9 per year in
Australia.
The model predicts that, under the screening program, the
number of CF babies in Australia is reduced to 14.0 CF infants
per 100,000 pregnancies or 41.4 per annum (from 100.9), a
59% reduction. The proportion of initial and subsequent chil-
dren with CF, and the cost of screening for and managing CF
in both initial and subsequent populations are provided in
Table 3.
The incremental cost of screening first children is estimated
to be $16.6 million–$13.4 million=$3.2 million/100,000 (i.e.
the cost offset of reduced treatment of CF does not outweigh
the cost of screening). The incremental cost per CF birth
averted in initial pregnancies is $150,000. Whether this repre-
sents value for money is uncertain as no threshold for this out-
come measure exists. However, the reduced treatment costs in
subsequent births are significant, particularly since a large pro-
portion of identified non-carriers are not screened in subsequentTable 3
Estimated reduction in CF under screening programs.
Initial child
No screening Scr
CF infants per 100,000 births 40.00 18.
Cost (screening and sequelae included) per 100,000 births $13.4 million $16
Incremental screening cost/CF birth averted $150,000
a This is a weighted mean of the initial and subsequent children, allowing for thepregnancies. When weighted to reflect the relative sizes of the
first and subsequent infant populations, the model estimates a
net cost saving associated with a national screening program
of $2.5 million/100,000 pregnancies.
3.1. Sensitivity analysis
The model was insensitive to the cost of CVS and termina-
tion, the infant mortality risk of CVS, and the assumptions con-
cerning whether parents abstain, pursue IVF or PND. The
results for the remaining parameters for the initial infant only
are presented graphically in Fig. 2.
If subsequent infants are included in the sensitivity analysis,
all scenarios are cost saving with the exception of two. First, if
the lifetime cost of CF management is reduced by 50% (to
$168,000), the cost of the screening program per infant across
both initial and subsequent births is $9.99. The cost per CF
birth averted in this case is $49,928. Second, if the carrier rate
is reduced to 2% (instead of the baseline rate of 4%), the cost
is $23.95, with a cost per CF birth averted of $478,946.
4. Discussion and conclusions
We have shown that CF carrier screening can reduce CF in
Australia. While carrier screening results in an incremental in-
crease in cost per CF birth averted for the first pregnancy
screened, substantial savings in subsequent pregnancies are
likely. The sensitivity analysis suggests that the base case result
is most sensitive to the cost of the test, the probability of termi-
nation following a positive CVS test, the lifetime cost of CF
management and the carrier rate. Of these, the cost of the test
is the most uncertain parameter. In this study, no reduction in
cost has been made to reflect economies of scale; doing so
would reduce the incremental cost associated with testing in
initial pregnancies, and increase the expected cost saving across
all pregnancies. When considering initial pregnancies only, the
cost of the test would have to fall to $80 to make the program
cost-saving.
Relative to the work of Maxwell et al. [9], the findings in this
study are more suggestive of a screening program recouping costs
in terms of reduced incidence of CF, and hence reduced costs of
care. The reason for this divergence is two-fold. Firstly, we have
included the impact of information on subsequent pregnancy
choices. This is important as many parents will require no screen-
ing for subsequent pregnancies, and those who are carriers may
make decisions which reduce the overall prevalence of CF births.Subsequent children All children a
eening No screening Screening No screening Screening
79 30.00 10.81 34.03 14.02
.6 million $10.1 million $3.6 million $11.5 million $9.0 million
−$339,000 (cost saving) −$125,000 (cost saving)
relative sizes of the two populations.
-$200
Carrier rate (0.06,0.02)
Probability termination if CVS +ve (1,0.3)
Cost of test (-50%,50%)
Lifetime cost of CF (-50%,50%)
Probability CVS if both parents +ve (1,0.75)
Test sensitivity (0.85,1.00)
Probability male tests if female +ve (1,0.84)
Probability female tests (preconceptual) (0.1,1)
Test specificity (1,0.99)
Probability female tests (prenatal) (0.5,1)
Cost/CF birth averted ($'000s)
$0 $200 $400 $600 $800 $1,000 $1,200 $1,400 $1,600 $1,800
Fig. 2. Univariate sensitivity analysis (initial infant only). Note that the order of the values of parameters within the brackets indicates the value which gives the lower
and upper estimate of cost/CF birth averted.
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the cost of treating a CF individual [11]. In some regards, the es-
timates of Van Gool et al. are likely to underestimate the cost of a
CF case as they ignore issues surrounding productivity, both of
the CF individual and their parent or carer; however, since this
is only of relevance if a societal perspective is taken.
An associated practical issue which might be considered in
future work is whether public subsidy of the sequelae of a car-
rier screening program is appropriate. For example, if a couple
is identified to be carriers, should society meet the costs of IVF
if the couple chooses to pursue assisted reproduction? This
issue is beyond the scope of this work, but is an important phil-
osophical and practical issue which may stem from a universal
screening program.
This work illustrates the difficulties of economic evalua-
tion in this type of intervention. The choice of outcome is con-
tentious for two reasons. Firstly, a screening program provides
information likely to be valued independent of health gain
(e.g. through reassurance). Within standard health economic
evaluation frameworks, health is the core outcome resulting
from an intervention, thus ignoring these non-health benefits
[13]. The second reason is that the changes in behaviour resulting
from screening occur in multiple dimensions. Screening for CF
reduces CF incidence, but also impacts on the number of termina-
tions and couples abstaining from reproduction. Economic evalu-
ation is usually reliant on combining all outcomes into a common
outcome measurement, (e.g. the QALY). However, estimating
QALYs based on CF babies averted, or couples abstaining from
reproduction are almost impossible and would involve a series
of unpalatable or unrealistic assumptions [14].
In conclusion, when initial and subsequent pregnancies are
considered together, carrier screening for CF is cost-effective
when analysed in the context of the Australian health care sys-
tem. The generalisability of the conclusion to other countries
is uncertain, due to different practices towards the manage-
ment of people with CF, or couples planning or going throughpregnancy. Costs differ between countries, as do conventions
regarding discounting of future events. However, our model
can be easily replicated and adopted by future researchers to
examine the cost-effectiveness of carrier screening in other
settings. Translating this information to healthcare policy is
the next challenge.Acknowledgements
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